BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 2575602)

  • 1. Recent advances in the management of gastric acid hypersecretion in patients with Zollinger-Ellison syndrome.
    Maton PN; Gardner JD; Jensen RT
    Gastroenterol Clin North Am; 1989 Dec; 18(4):847-63. PubMed ID: 2575602
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Famotidine: effective treatment of Zollinger-Ellison syndrome.
    Howard JM; Vinayek R; Maton PN; Wank SA; Gardner JD; Jensen RT
    J Clin Gastroenterol; 1987; 9 Suppl 2():23-5. PubMed ID: 2887615
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Famotidine, a new, potent, long-acting histamine H2-receptor antagonist: comparison with cimetidine and ranitidine in the treatment of Zollinger-Ellison syndrome.
    Howard JM; Chremos AN; Collen MJ; McArthur KE; Cherner JA; Maton PN; Ciarleglio CA; Cornelius MJ; Gardner JD; Jensen RT
    Gastroenterology; 1985 Apr; 88(4):1026-33. PubMed ID: 2857672
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [24-hour intragastric acid profile in a ZES patient with H2 blockers].
    Dammann HG; Müller P; Simon B; Kommerell B
    Z Gastroenterol; 1984 Jun; 22(6):318-20. PubMed ID: 6147052
    [No Abstract]   [Full Text] [Related]  

  • 5. Famotidine in the therapy of gastric hypersecretory states.
    Vinayek R; Howard JM; Maton PN; Wank SA; Slaff JI; Gardner JD; Jensen RT
    Am J Med; 1986 Oct; 81(4B):49-59. PubMed ID: 2877575
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of the effectiveness of ranitidine and cimetidine in inhibiting acid secretion in patients with gastric hypersecretory states.
    Jensen RT; Collen MJ; McArthur KE; Howard JM; Maton PN; Cherner JA; Gardner JD
    Am J Med; 1984 Nov; 77(5B):90-105. PubMed ID: 6150641
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of acid suppressants in patients with Zollinger-Ellison syndrome.
    Maton PN
    Aliment Pharmacol Ther; 1991; 5 Suppl 1():25-35. PubMed ID: 1679671
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Changing patterns in presentation and management of the Zollinger-Ellison syndrome in Northern Ireland, 1970-1988.
    Collins JS; Buchanan KD; Kennedy TL; Johnston CF; Ardill JE; Sloan JM; McIlrath EM; Russell C
    Q J Med; 1991 Mar; 78(287):215-25. PubMed ID: 1675471
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Omeprazole in Zollinger-Ellison syndrome. Effects of a single dose and of long-term treatment in patients resistant to histamine H2-receptor antagonists.
    Lambers CB; Lind T; Moberg S; Jansen JB; Olbe L
    N Engl J Med; 1984 Mar; 310(12):758-61. PubMed ID: 6142418
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Omeprazole in the treatment of Zollinger-Ellison syndrome and histamine H2-antagonist refractory ulcers.
    Meijer JL; Jansen JB; Lamers CB
    Digestion; 1989; 44 Suppl 1():31-9. PubMed ID: 2575060
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Strong inhibition of gastric acid secretion: when is it justifiable?].
    Dobrilla G; Amplaz S; Benvenuti S; Bertozzo A
    G Clin Med; 1990; 71(8-9):521-6. PubMed ID: 1980653
    [No Abstract]   [Full Text] [Related]  

  • 12. Diagnosis and management of the Zollinger-Ellison syndrome.
    Jensen RT; Pandol SJ; Collen MJ; Raufman JP; Gardner JD
    J Clin Gastroenterol; 1983; 5 Suppl 1():123-31. PubMed ID: 6140281
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Uncertainties in the management of the Zollinger-Ellison Syndrome.
    Malagelada JR
    Gastroenterology; 1983 Jan; 84(1):188-9. PubMed ID: 6128287
    [No Abstract]   [Full Text] [Related]  

  • 14. [Management of the hypersecretion of acid in Zollinger-Ellison syndrome (ZES)].
    Varas MJ; López A; Gordillo J
    Rev Esp Enferm Apar Dig; 1989 Apr; 75(4):419-20. PubMed ID: 2568007
    [No Abstract]   [Full Text] [Related]  

  • 15. Famotidine. The ACG Committee on FDA-Related Matters with primary authorship by G. Friedman. American College of Gastroenterology.
    Am J Gastroenterol; 1987 Jun; 82(6):504-6. PubMed ID: 2883885
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [25 years of gastric acid blockers].
    Lamers CB
    Ned Tijdschr Geneeskd; 1999 Dec; 143(50):2501-4. PubMed ID: 10627749
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Parenteral control of gastric acid hypersecretion in patients with Zollinger-Ellison syndrome.
    Vinayek R; Hahne WF; Euler AR; Norton JA; Jensen RT
    Dig Dis Sci; 1993 Oct; 38(10):1857-65. PubMed ID: 8104773
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Omeprazole: a new approach to gastric acid suppression.
    Buhl K; Clearfield HR
    Am Fam Physician; 1990 Apr; 41(4):1225-7. PubMed ID: 2321497
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of patients with Zollinger-Ellison syndrome.
    Mignon M; Pospai D; Forestier S; Vatier J; Vallot T
    Clin Ther; 1993; 15 Suppl B():22-31. PubMed ID: 8205592
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reliability of symptoms in assessing control of gastric acid secretion in patients with Zollinger-Ellison syndrome.
    Raufman JP; Collins SM; Pandol SJ; Korman LY; Collen MJ; Cornelius MJ; Feld MK; McCarthy DM; Gardner JD; Jensen RT
    Gastroenterology; 1983 Jan; 84(1):108-13. PubMed ID: 6128284
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.